DataMeds AI Restructures Pharmacy Division to Drive Healthcare Growth
New York, Tuesday, 11 August 2026.
DataMeds AI has reorganized its pharmacy operations under a new division, Corexa Health. The strategic shift separates core pharmacy services to prepare for upcoming healthcare expansion.
Corporate Restructuring and Division Launch
DataMeds AI, Inc. (NASDAQ: MEDS) officially announced the completion of its pharmacy subsidiary rebranding on August 10, 2026 [1][3]. The Tampa-based Health IT firm has consolidated its pharmacy and pharmacy hub entities under a newly established division known as Corexa Health, LLC [1][2]. As part of this structural adjustment, the pharmacy entity has been renamed Corexa Pharmacy, LLC, while the pharmacy hub entity is now designated as Corexa Tech & Hub, LLC [1][3]. The company’s nationally-licensed pharmaceutical distribution subsidiary, Wellgistics, LLC, will retain its existing name to maintain continuity in distribution operations [2][3]. This reorganization is designed to create a clear distinction between the company’s pharmacy-focused divisions and its upcoming healthcare service lines [1][2].
Technology Integration and Strategic Licensing
The restructuring supports the broader deployment of the company’s proprietary artificial intelligence platform, EinsteinRx™ [1][3]. DataMeds AI is currently integrating commercial healthcare delivery intellectual property licensed from DataVault AI Inc. (NASDAQ: DVLT) into its existing PharmacyChain™ platform [1][2]. This blockchain-enabled smart contracts platform is utilized for health data monetization and pharmaceutical serialization tracking [1][3]. Gerald Commissiong, Interim Co-CEO of DataMeds AI, stated that the expansion of the EinsteinRx platform within the pharmacy hub is a key priority during this integration phase [2][3]. The strategic alignment aims to streamline technology infrastructure to better serve healthcare providers across the United States [1][2].
Expansion Plans and Risk Disclosures
Looking forward, the company is pursuing the acquisition of Tollo Health, LLC, a medical foods manufacturer and provider of the “Health Lives Here” consumer healthcare app [1][2]. This potential acquisition is being developed in partnership with National Football League Alumni Health (NFLAH) to enhance customer acquisition marketing [1][3]. DataMeds AI also intends to acquire the QOLPOM intellectual property portfolio, which includes biometric drug compliance and drone delivery technology [2][3]. However, the company notes that transactions such as these may not be completed on anticipated terms or timelines [1][3]. Forward-looking statements indicate that operational goals involving telemedicine and diagnostic laboratory services remain subject to regulatory approval and licensure [1][2].